

---

## Product Datasheet

### IL-6 receptor antibody (orb396139)

Enables Biocompatibility  
**Description**

Mouse monoclonal antibody to IL-6 receptor.

**Species/Host**

Human

**Reactivity**

Human

**Conjugation**

Unconjugated

**Tested Applications**

ELISA

**Immunogen**

The original antibody was generated by CDR grafting of mouse PM-1 antibody onto human REI and NEW framework regions to create rhPM-1.

**Target**

IL-6 receptor

**Preservatives**

PBS with 0.02% Proclin 300.

**Concentration**

1 mg/ml

**Storage**

Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

**Note**

For research use only

**Application notes**

This antibody is derived from the parental mouse clone PM-1 (PM1). Tocilizumab (TCZ) binds and neutralizes IL-6R, resulting in the inhibition of various IL-6-mediated biological activities, including inflammation-related, immunomodulatory and tissue/matrix remodelling effects. This antibody is extensively explored for its therapeutic potential in treatment of rheumatoid arthritis (PMID: 25099958; 9836380). Tocilizumab can be used in ELISA assays and is able to inhibit the growth of IL-6-dependent tumor cell lines. It inhibits sIL-6R and mIL-6R-mediated signaling. A study reported that a combination of tocilizumab and methotrexate (MTX) results in greater inhibition of joint damage and improvement in physical function than does MTX alone (PMID: 21360490). Treatment with tocilizumab results in significant improvement, maintained over time, of polyarticular-course juvenile idiopathic arthritis (pcJIA) signs and symptoms and has a safety profile consistent with that for adults with rheumatoid arthritis (PMID: 24834925).

**Isotype**

IgG1